Janney Montgomery Scott initiated coverage on shares of Questcor Pharmaceuticals (NASDAQ: QCOR) in a research report released on Thursday morning. The firm issued a buy rating and a $40.00 price target on the stock.
QCOR has been the subject of a number of other recent research reports. Analysts at TheStreet upgraded shares of Questcor Pharmaceuticals from a hold rating to a buy rating in a research note to investors on Thursday. Separately, analysts at Mizuho upgraded shares of Questcor Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Thursday. They now have a $41.00 price target on the stock, up previously from $28.00. Finally, analysts at Lazard Capital Markets reiterated a buy rating on shares of Questcor Pharmaceuticals in a research note to investors on Monday, December 31st. They now have a $74.00 price target on the stock.
Six equities research analysts have rated the stock with a buy rating, and three have assigned a hold rating to the company’s stock. The stock presently has an average rating of overweight and a consensus target price of $44.71.
Shares of Questcor Pharmaceuticals opened at 30.90 on Thursday. Questcor Pharmaceuticals has a one year low of $17.25 and a one year high of $58.91. The stock’s 50-day moving average is currently $26.76. The company has a market cap of $1.812 billion and a P/E ratio of 11.94.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
